Marilyn Huang1, Priyanka Kamath2, Matthew Schlumbrecht2, Feng Miao3, Devin Driscoll4, Sean Oldak4, Brian Slomovitz2, Tulay Koru-Sengul5, Sophia George2. 1. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States of America. Electronic address: m.huang@med.miami.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States of America. 3. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States of America. 4. University of Miami Miller School of Medicine, Miami, FL, United States of America. 5. Division of Biostatistics, Department of Public Health Sciences, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States of America.
Abstract
OBJECTIVE: Germline mutations occur in approximately 25% of patients with epithelial ovarian cancers while somatic BRCA mutations are estimated at 5-7%. The objectives of this study were to determine the rate of germline and somatic testing in women with ovarian cancer and to identify disparities in testing at a comprehensive cancer center (CCC) and a safety net hospital (SNH). METHODS: Patients treated for ovarian cancer from 2011 to 2016 were included. Clinicopathologic data were abstracted from the electronic medical records. Logistic regression modeling were performed to calculate odds ratios (OR) and corresponding 95% confidence intervals (95%CI). RESULTS: Out of 367 women, 55.3% completed germline testing; 27.0% received somatic testing. Women at the CCC were more likely to be tested for germline (60.4% vs 38.1%, p ≤ 0.001) and somatic (34.3% vs 2.4%, p ≤ 0.001) mutations than those at the SNH. Patients with Medicare (aOR = 0.51, 95%CI 0.28-0.94, p = 0.032) or Medicaid (aOR = 0.42, 95%CI 0.18-0.99, p = 0.048) were less likely to receive germline testing than those privately insured. Patients with Medicaid were less likely to receive somatic testing (aOR = 0.15, 95%CI 0.04-0.62, p = 0.009) than those privately insured. Women with disease recurrence had a higher likelihood of being tested for germline (OR = 3.64, 95%CI 1.94-6.83, P < 0.001) and somatic (OR = 7.89, 95%CI 3.41-18.23, p < 0.001) mutations. There was no difference in germline or somatic testing by race/ethnicity. CONCLUSIONS: Disparities in both germline and somatic testing exist. Understanding and overcoming barriers to testing may improve cancer-related mortality by allowing for more tailored treatments as well as for improved cascade testing.
OBJECTIVE: Germline mutations occur in approximately 25% of patients with epithelial ovarian cancers while somatic BRCA mutations are estimated at 5-7%. The objectives of this study were to determine the rate of germline and somatic testing in women with ovarian cancer and to identify disparities in testing at a comprehensive cancer center (CCC) and a safety net hospital (SNH). METHODS:Patients treated for ovarian cancer from 2011 to 2016 were included. Clinicopathologic data were abstracted from the electronic medical records. Logistic regression modeling were performed to calculate odds ratios (OR) and corresponding 95% confidence intervals (95%CI). RESULTS: Out of 367 women, 55.3% completed germline testing; 27.0% received somatic testing. Women at the CCC were more likely to be tested for germline (60.4% vs 38.1%, p ≤ 0.001) and somatic (34.3% vs 2.4%, p ≤ 0.001) mutations than those at the SNH. Patients with Medicare (aOR = 0.51, 95%CI 0.28-0.94, p = 0.032) or Medicaid (aOR = 0.42, 95%CI 0.18-0.99, p = 0.048) were less likely to receive germline testing than those privately insured. Patients with Medicaid were less likely to receive somatic testing (aOR = 0.15, 95%CI 0.04-0.62, p = 0.009) than those privately insured. Women with disease recurrence had a higher likelihood of being tested for germline (OR = 3.64, 95%CI 1.94-6.83, P < 0.001) and somatic (OR = 7.89, 95%CI 3.41-18.23, p < 0.001) mutations. There was no difference in germline or somatic testing by race/ethnicity. CONCLUSIONS: Disparities in both germline and somatic testing exist. Understanding and overcoming barriers to testing may improve cancer-related mortality by allowing for more tailored treatments as well as for improved cascade testing.
Authors: Stacy W Gray; Rebecca A Ottesen; Madeline Currey; Mihaela Cristea; Janet Nikowitz; Susan Shehayeb; Vanessa Lozano; Julie Hom; Julie Kilburn; Lisa N Lopez; Sam Wing; Ernesto Sosa; Jenny Shen; Michael Morris; Bedros Dilsizian; Thomas Joseph; James Shen; Camille Adeimy; Tanyanika Phillips; Bahareh Bahadini; Joyce C Niland Journal: JCO Clin Cancer Inform Date: 2022-09
Authors: Grace A Lin; Julia R Trosman; Michael P Douglas; Christine B Weldon; Maren T Scheuner; Allison Kurian; Kathryn A Phillips Journal: J Genet Couns Date: 2021-07-07 Impact factor: 2.537
Authors: Jenny Lin; Ravi N Sharaf; Rachel Saganty; Danyal Ahsan; Julia Feit; Andrea Khoury; Hannah Bergeron; Eloise Chapman-Davis; Evelyn Cantillo; Kevin Holcomb; Stephanie V Blank; Ying Liu; Charlene Thomas; Paul J Christos; Drew N Wright; Steven Lipkin; Kenneth Offit; Melissa K Frey Journal: Gynecol Oncol Date: 2021-05-19 Impact factor: 5.304
Authors: Sophia H L George; Talia Donenberg; Cheryl Alexis; Vincent DeGennaro; Hedda Dyer; Sook Yin; Jameel Ali; Raleigh Butler; Sheray N Chin; DuVaughn Curling; Dwight Lowe; John Lunn; Theodore Turnquest; Gilian Wharfe; Danielle Cerbon; Priscila Barreto-Coelho; Matthew P Schlumbrecht; Mohammad R Akbari; Steven A Narod; Judith E Hurley Journal: JAMA Netw Open Date: 2021-03-01
Authors: Emmanuel B Omole; Iqbal Aijaz; James Ellegate; Emily Isenhart; Mohamed M Desouki; Michalis Mastri; Kristen Humphrey; Emily M Dougherty; Spencer R Rosario; Kent L Nastiuk; Joyce E Ohm; Kevin H Eng Journal: Cancers (Basel) Date: 2022-09-28 Impact factor: 6.575
Authors: Yan You; Lei Li; Junliang Lu; Huanwen Wu; Jing Wang; Jie Gao; Ming Wu; Zhiyong Liang Journal: Front Oncol Date: 2020-03-10 Impact factor: 6.244
Authors: Scott E Jordan; Samantha Spring; Priyanka Kamath; Matthew P Schlumbrecht; J Matthew Pearson; Abdulrahman K Sinno; Sophia H L George; Marilyn Huang Journal: Gynecol Oncol Rep Date: 2020-10-28